DTIL Quote, Financials, Valuation and Earnings

Lifeward has a net margin of -70913.79% compared to Precision BioSciences's net margin of -96.03%. Precision BioSciences's return on equity of -38.91% beat Lifeward's return on equity of -92.59%.

Precision BioSciences has a consensus price target of $30.50, signalling upside risk potential of 574.78%. On the other hand Lifeward has an analysts' consensus of $8.67 which suggests that it could grow by 1071.17%. Given that Lifeward has higher upside potential than Precision BioSciences, analysts believe Lifeward is more attractive than Precision BioSciences.

Precision BioSciences has a beta of 1.428, which suggesting that the stock is 42.833% more volatile than S&P 500. In comparison Lifeward has a beta of 0.016, suggesting its less volatile than the S&P 500 by 98.425%.

Precision BioSciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lifeward offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precision BioSciences pays -- of its earnings as a dividend. Lifeward pays out -- of its earnings as a dividend.

Precision BioSciences quarterly revenues are $29K, which are smaller than Lifeward quarterly revenues of $5M. Precision BioSciences's net income of -$20.6M is lower than Lifeward's net income of -$4.8M. Notably, Precision BioSciences's price-to-earnings ratio is 3.41x while Lifeward's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precision BioSciences is 0.70x versus 0.27x for Lifeward. Usually stocks with elevated PS ratios are considered overvalued.

Mersana Therapeutics has a net margin of -70913.79% compared to Precision BioSciences's net margin of -875.93%. Precision BioSciences's return on equity of -38.91% beat Mersana Therapeutics's return on equity of -533.43%.

Precision BioSciences has a consensus price target of $30.50, signalling upside risk potential of 574.78%. On the other hand Mersana Therapeutics has an analysts' consensus of $4.29 which suggests that it could grow by 1163.1%. Given that Mersana Therapeutics has higher upside potential than Precision BioSciences, analysts believe Mersana Therapeutics is more attractive than Precision BioSciences.

Precision BioSciences has a beta of 1.428, which suggesting that the stock is 42.833% more volatile than S&P 500. In comparison Mersana Therapeutics has a beta of 0.787, suggesting its less volatile than the S&P 500 by 21.338%.

Precision BioSciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mersana Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precision BioSciences pays -- of its earnings as a dividend. Mersana Therapeutics pays out -- of its earnings as a dividend.

Precision BioSciences quarterly revenues are $29K, which are smaller than Mersana Therapeutics quarterly revenues of $2.8M. Precision BioSciences's net income of -$20.6M is higher than Mersana Therapeutics's net income of -$24.1M. Notably, Precision BioSciences's price-to-earnings ratio is 3.41x while Mersana Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precision BioSciences is 0.70x versus 1.23x for Mersana Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

PAVmed has a net margin of -70913.79% compared to Precision BioSciences's net margin of -1105.92%. Precision BioSciences's return on equity of -38.91% beat PAVmed's return on equity of --.

Precision BioSciences has a consensus price target of $30.50, signalling upside risk potential of 574.78%. On the other hand PAVmed has an analysts' consensus of $11.50 which suggests that it could grow by 1900%. Given that PAVmed has higher upside potential than Precision BioSciences, analysts believe PAVmed is more attractive than Precision BioSciences.

Precision BioSciences has a beta of 1.428, which suggesting that the stock is 42.833% more volatile than S&P 500. In comparison PAVmed has a beta of 1.060, suggesting its more volatile than the S&P 500 by 5.988%.

Precision BioSciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PAVmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precision BioSciences pays -- of its earnings as a dividend. PAVmed pays out -- of its earnings as a dividend.

Precision BioSciences quarterly revenues are $29K, which are larger than PAVmed quarterly revenues of $8K. Precision BioSciences's net income of -$20.6M is lower than PAVmed's net income of $19M. Notably, Precision BioSciences's price-to-earnings ratio is 3.41x while PAVmed's PE ratio is 0.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precision BioSciences is 0.70x versus 8.46x for PAVmed. Usually stocks with elevated PS ratios are considered overvalued.

Phio Pharmaceuticals has a net margin of -70913.79% compared to Precision BioSciences's net margin of --. Precision BioSciences's return on equity of -38.91% beat Phio Pharmaceuticals's return on equity of --.

Precision BioSciences has a consensus price target of $30.50, signalling upside risk potential of 574.78%. On the other hand Phio Pharmaceuticals has an analysts' consensus of $14.00 which suggests that it could grow by 488.24%. Given that Precision BioSciences has higher upside potential than Phio Pharmaceuticals, analysts believe Precision BioSciences is more attractive than Phio Pharmaceuticals.

Precision BioSciences has a beta of 1.428, which suggesting that the stock is 42.833% more volatile than S&P 500. In comparison Phio Pharmaceuticals has a beta of 0.910, suggesting its less volatile than the S&P 500 by 9.016%.

Precision BioSciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precision BioSciences pays -- of its earnings as a dividend. Phio Pharmaceuticals pays out -- of its earnings as a dividend.

Precision BioSciences quarterly revenues are $29K, which are larger than Phio Pharmaceuticals quarterly revenues of --. Precision BioSciences's net income of -$20.6M is lower than Phio Pharmaceuticals's net income of -$1.8M. Notably, Precision BioSciences's price-to-earnings ratio is 3.41x while Phio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precision BioSciences is 0.70x versus -- for Phio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.